Transcranial Pulse Stimulation with Ultrasound in Alzheimer's Disease-A New Navigated Focal Brain Therapy.
Authors: Beisteiner R, Matt E, Fan C, Baldysiak H, Schönfeld M, Philippi Novak T, Amini A, Aslan T, Reinecke R, Lehrner J, Weber A, Reime U, Goldenstedt C, Marlinghaus E, Hallett M, Lohse-Busch H
Ultrasound-based brain stimulation techniques may become a powerful new technique to modulate the human brain in a focal and targeted manner. However, for clinical brain stimulation no certified systems exist and the current techniques have to be further developed. Here, a clinical sonication technique is introduced, based on single ultrashort ultrasound pulses (transcranial pulse stimulation, TPS) which markedly differs from existing focused ultrasound techniques. In addition, a first clinical study using ultrasound brain stimulation and first observations of long term effects are presented. Comprehensive feasibility, safety, and efficacy data are provided. They consist of simulation data, laboratory measurements with rat and human skulls and brains, in vivo modulations of somatosensory evoked potentials (SEP) in healthy subjects (sham controlled) and clinical pilot data in 35 patients with Alzheimer's disease acquired in a multicenter setting (including neuropsychological scores and functional magnetic resonance imaging (fMRI)). Preclinical results show large safety margins and dose dependent neuromodulation. Patient investigations reveal high treatment tolerability and no major side effects. Neuropsychological scores improve significantly after TPS treatment and improvement lasts up to three months and correlates with an upregulation of the memory network (fMRI data). The results encourage broad neuroscientific application and translation of the method to clinical therapy and randomized sham-controlled clinical studies.
Introduction
Purpose
Transcranial ultrasound stimulation
Study Objective
To introduce a new clinical transcranial pulse stimulation (TPS) ultrasound technique and evaluate its feasibility, safety, and preliminary efficacy in preclinical tests and a pilot study of patients with Alzheimer's disease.
Animal model / Human subject
Rat (Rattus norvegicus; strain not reported; age not reported; sex not reported); Human (Homo sapiens; healthy subjects and 35 Alzheimer's patients; age not reported; sex not reported)
Disease model
Alzheimer's disease
Targeted brain region(s)
Somatosensory Cortex
Outcomes and Safety
Summary of Outcomes
Transcranial pulse stimulation (TPS) was safe and produced dose‑dependent neuromodulation (changes in somatosensory evoked potentials) and clinically meaningful cognitive benefits in Alzheimer’s patients (improved CERAD CTS/LR, memory and verbal scores and increased hippocampal/memory‑network connectivity lasting up to three months) with no major adverse effects. Successful stimulation parameters included single ultrashort ~3 µs pulses at ~0.2–0.3 mJ mm−2 (system limit 0.25 mJ mm−2 at 4 Hz), pulse rates of 1–5 Hz, and cumulative pulse counts showing dose dependence (10/100/1000 pulses in healthy subjects; clinical treatments used higher cumulative pulses up to the system maximums).
Duration of biological effect
3 months
Safety-related matter
Preclinical (rats) and clinical (10 healthy subjects and 35 AD patients) assessments indicated high tolerability and no major side effects — animal studies showed no intracranial bleeding, histological abnormalities, or BBB damage and MRI up to 150‑fold human dose showed no brain injury. Patient follow‑up reported no relevant side effects (center 1: 4% headache, 3% mood deterioration, 93% none), mostly VAS pain/pressure = 0, and no hemorrhages, edema, or new intracranial pathology on MRI.
Brain Region
Ultrasound Parameters
FUS Mode
pulsed
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: None
Treatment frequency
multiple sessions
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search